Disposition and metabolism of (14)C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.

Autor: Dubbelman AC, Upthagrove A, Beijnen JH, Marchetti S, Tan E, Krone K, Anand S, Schellens JH
Zdroj: Cancer Chemotherapy & Pharmacology; Nov2012, Vol. 70 Issue 5, p653-663, 11p
Databáze: Complementary Index
Externí odkaz: